EU Regulator Advises Extra Birth Control Precautions for Patients of Lilly's Mounjaro
By Kelly Cloonan
European drug regulators advised women who take birth control pills and Eli Lilly's Mounjaro to take extra steps to ensure their contraception remains effective while on the diabetes and weight-loss drug.
The European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, said it now advises patients on birth control pills to add a backup method of contraception for four weeks after starting Mounjaro, and for four weeks after each dose increase.
The CHMP said it alternatively advises Mounjaro patients to switch to a non-oral method of contraception.
The CHMP said its guidance would be disseminated to healthcare professionals by Eli Lilly following a decision by the European Commission.
Women who can become pregnant and are using Mounjaro are recommended to use contraception.
The CHMP--which is responsible for assessing the quality, safety and efficacy of medicines in the EU, and issuing recommendations to the European Commission--said there is limited information available on the effect of tirzepatide on the efficacy of oral contraceptives in women with obesity, overweight or type 2 diabetes mellitus.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
November 13, 2026 08:01 ET (13:01 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Growth Stocks to Buy While They’re Still Undervalued
3 of the Best Core Stocks to Own
3 Great New ETFs From 2026
Retirees: 5 Reasons to Consider Index Funds and ETFs
United States